Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

The mammalian CTLH complex is an E3 ubiquitin ligase that targets its subunit muskelin for degradation.

Maitland MER, Onea G, Chiasson CA, Wang X, Ma J, Moor SE, Barber KR, Lajoie GA, Shaw GS, Schild-Poulter C.

Sci Rep. 2019 Jul 8;9(1):9864. doi: 10.1038/s41598-019-46279-5.

2.

Cancer Clinical Investigators Should Converge with Pharmacometricians.

Maitland ML, O'Cearbhaill RE, Gobburu J.

Clin Cancer Res. 2019 Sep 1;25(17):5182-5184. doi: 10.1158/1078-0432.CCR-19-1067. Epub 2019 Jun 27.

PMID:
31248883
3.

Regulation of c-Raf Stability through the CTLH Complex.

McTavish CJ, Bérubé-Janzen W, Wang X, Maitland MER, Salemi LM, Hess DA, Schild-Poulter C.

Int J Mol Sci. 2019 Feb 21;20(4). pii: E934. doi: 10.3390/ijms20040934.

4.

Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology.

Dercle L, Connors DE, Tang Y, Adam SJ, Gönen M, Hilden P, Karovic S, Maitland M, Moskowitz CS, Kelloff G, Zhao B, Oxnard GR, Schwartz LH.

JCO Clin Cancer Inform. 2018 Dec;2:1-12. doi: 10.1200/CCI.17.00137.

5.

A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.

Sehdev A, Karrison T, Zha Y, Janisch L, Turcich M, Cohen EEW, Maitland M, Polite BN, Gajewski TF, Salgia R, Pinto N, Bissonnette MB, Fleming GF, Ratain MJ, Sharma MR.

Cancer Chemother Pharmacol. 2018 Aug;82(2):309-317. doi: 10.1007/s00280-018-3619-3. Epub 2018 Jun 9.

6.

Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study.

Claret L, Pentafragka C, Karovic S, Zhao B, Schwartz LH, Maitland ML, Bruno R.

Cancer Chemother Pharmacol. 2018 Jul;82(1):49-54. doi: 10.1007/s00280-018-3587-7. Epub 2018 Apr 26.

PMID:
29700575
7.

Participation in active play of children who use lower extremity prostheses: An exploratory questionnaire.

Kerfeld C, Jirikowic T, Allyn KJ, Maitland ME.

Prosthet Orthot Int. 2018 Aug;42(4):437-445. doi: 10.1177/0309364618767139. Epub 2018 Apr 6.

PMID:
29623809
8.

Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.

Maitland ML, Piha-Paul S, Falchook G, Kurzrock R, Nguyen L, Janisch L, Karovic S, McKee M, Hoening E, Wong S, Munasinghe W, Palma J, Donawho C, Lian GK, Ansell P, Ratain MJ, Hong D.

Br J Cancer. 2018 Apr;118(8):1042-1050. doi: 10.1038/s41416-018-0020-2. Epub 2018 Mar 19.

9.

Protease-Mediated Suppression of DRG Neuron Excitability by Commensal Bacteria.

Sessenwein JL, Baker CC, Pradhananga S, Maitland ME, Petrof EO, Allen-Vercoe E, Noordhof C, Reed DE, Vanner SJ, Lomax AE.

J Neurosci. 2017 Nov 29;37(48):11758-11768. doi: 10.1523/JNEUROSCI.1672-17.2017. Epub 2017 Oct 31.

10.

Inhibition of HDAC6 activity through interaction with RanBPM and its associated CTLH complex.

Salemi LM, Maitland MER, Yefet ER, Schild-Poulter C.

BMC Cancer. 2017 Jul 1;17(1):460. doi: 10.1186/s12885-017-3430-2.

11.

Cell signalling pathway regulation by RanBPM: molecular insights and disease implications.

Salemi LM, Maitland MER, McTavish CJ, Schild-Poulter C.

Open Biol. 2017 Jun;7(6). pii: 170081. doi: 10.1098/rsob.170081. Review.

12.

Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment.

Abou-Alfa GK, Lewis LD, LoRusso P, Maitland M, Chandra P, Cheeti S, Colburn D, Williams S, Simmons B, Graham RA.

Cancer Chemother Pharmacol. 2017 Jul;80(1):29-36. doi: 10.1007/s00280-017-3315-8. Epub 2017 May 18.

13.

PharmGKB summary: sorafenib pathways.

Gong L, Giacomini MM, Giacomini C, Maitland ML, Altman RB, Klein TE.

Pharmacogenet Genomics. 2017 Jun;27(6):240-246. doi: 10.1097/FPC.0000000000000279. Review. No abstract available.

14.

What people want in a prosthetic foot: A focus group study.

Fogelberg DJ, Allyn KJ, Smersh M, Maitland ME.

J Prosthet Orthot. 2016 Oct;28(4):145-151. doi: 10.1097/JPO.0000000000000102. No abstract available.

15.

A Pharmacokinetic and Safety Study of Trebananib, an Fc-Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction.

Wu B, Lewis LD, Harvey RD, Rasmussen E, Gamelin E, Sun YN, Friberg G, Koyner JL, Dowlati A, Maitland ML.

Clin Pharmacol Ther. 2017 Aug;102(2):313-320. doi: 10.1002/cpt.617. Epub 2017 Jun 9.

PMID:
28074547
16.

First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors.

Forero A, Bendell JC, Kumar P, Janisch L, Rosen M, Wang Q, Copigneaux C, Desai M, Senaldi G, Maitland ML.

Invest New Drugs. 2017 Jun;35(3):298-306. doi: 10.1007/s10637-016-0420-1. Epub 2017 Jan 3.

PMID:
28050790
17.

Improving clinical trial design through quantitative pharmacology.

Maitland ML.

Clin Adv Hematol Oncol. 2016 Aug;14(8):606-8. No abstract available.

PMID:
27487104
18.

Patient-Level Adverse Event Patterns in a Single-Institution Study of the Multi-Kinase Inhibitor Sorafenib.

Karovic S, Shiuan EF, Zhang SQ, Cao H, Maitland ML.

Clin Transl Sci. 2016 Oct;9(5):260-266. doi: 10.1111/cts.12408. Epub 2016 Jul 21.

19.

First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors.

Li T, LoRusso P, Maitland ML, Ou SH, Bahceci E, Ball HA, Park JW, Yuen G, Tolcher A.

J Hematol Oncol. 2016 Mar 10;9:23. doi: 10.1186/s13045-016-0254-5.

20.

Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling.

Li CH, Bies RR, Wang Y, Sharma MR, Karovic S, Werk L, Edelman MJ, Miller AA, Vokes EE, Oto A, Ratain MJ, Schwartz LH, Maitland ML.

Clin Transl Sci. 2016 Feb;9(1):43-50. doi: 10.1111/cts.12384. Epub 2016 Jan 21.

21.

Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death.

Zimmerman EI, Gibson AA, Hu S, Vasilyeva A, Orwick SJ, Du G, Mascara GP, Ong SS, Chen T, Vogel P, Inaba H, Maitland ML, Sparreboom A, Baker SD.

Cancer Res. 2016 Jan 1;76(1):117-26. doi: 10.1158/0008-5472.CAN-15-0694. Epub 2015 Dec 17.

22.

Large deviation analysis of a simple information engine.

Maitland M, Grosskinsky S, Harris RJ.

Phys Rev E Stat Nonlin Soft Matter Phys. 2015 Nov;92(5):052136. doi: 10.1103/PhysRevE.92.052136. Epub 2015 Nov 24.

PMID:
26651675
23.

Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics.

Geeleher P, Loboda A, Lenkala D, Wang F, LaCroix B, Karovic S, Wang J, Nebozhyn M, Chisamore M, Hardwick J, Maitland ML, Huang RS.

J Natl Cancer Inst. 2015 Aug 21;107(11). pii: djv247. doi: 10.1093/jnci/djv247. Print 2015 Nov.

24.

Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide.

O'Donnell PH, Karovic S, Karrison TG, Janisch L, Levine MR, Harris PJ, Polite BN, Cohen EE, Fleming GF, Ratain MJ, Maitland ML.

Clin Cancer Res. 2015 Nov 15;21(22):5092-9. doi: 10.1158/1078-0432.CCR-15-0427. Epub 2015 Jul 21.

25.

Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib.

Maitland ML, Xu CF, Cheng YC, Kistner-Griffin E, Ryan KA, Karrison TG, Das S, Torgerson D, Gamazon ER, Thomeas V, Levine MR, Wilson PA, Bing N, Liu Y, Cardon LR, Pandite LN, O'Connell JR, Cox NJ, Mitchell BD, Ratain MJ, Shuldiner AR.

Clin Cancer Res. 2015 Jan 15;21(2):365-72. doi: 10.1158/1078-0432.CCR-14-1683. Epub 2014 Nov 19.

26.

Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.

Innocenti F, Schilsky RL, Ramírez J, Janisch L, Undevia S, House LK, Das S, Wu K, Turcich M, Marsh R, Karrison T, Maitland ML, Salgia R, Ratain MJ.

J Clin Oncol. 2014 Aug 1;32(22):2328-34. doi: 10.1200/JCO.2014.55.2307. Epub 2014 Jun 23.

27.

Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.

Karovic S, Wen Y, Karrison TG, Bakris GL, Levine MR, House LK, Wu K, Thomeas V, Rudek MA, Wright JJ, Cohen EE, Fleming GF, Ratain MJ, Maitland ML.

Clin Pharmacol Ther. 2014 Jul;96(1):27-35. doi: 10.1038/clpt.2014.63. Epub 2014 Mar 17.

28.

Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.

Maitland ML, Levine MR, Lacouture ME, Wroblewski KE, Chung CH, Gordon IO, Szeto L, Ratko G, Soltani K, Kozloff MF, Hoffman PC, Salgia R, Carbone DP, Karrison TG, Vokes EE.

BMC Cancer. 2014 Jan 4;14:5. doi: 10.1186/1471-2407-14-5.

29.

Technical considerations in the development of circulating peptides as pharmacodynamic biomarkers for angiogenesis inhibitors.

Thomeas V, Chow S, Gutierrez JO, Karovic S, Wroblewski K, Kistner-Griffin E, Karrison TG, Maitland ML.

J Clin Pharmacol. 2014 Jun;54(6):682-7. doi: 10.1002/jcph.254. Epub 2014 Jan 17.

30.

Bayesian inference for longitudinal data with non-parametric treatment effects.

Müller P, Quintana FA, Rosner GL, Maitland ML.

Biostatistics. 2014 Apr;15(2):341-52. doi: 10.1093/biostatistics/kxt049. Epub 2013 Nov 26.

31.

Bicycle helmets: don't say something by not saying something.

Maitland ME.

Clin J Sport Med. 2013 Nov;23(6):415-6. doi: 10.1097/JSM.0000000000000037. No abstract available.

PMID:
24169296
32.

Institutional Profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation science.

Dolan ME, Maitland ML, O'Donnell PH, Nakamura Y, Cox NJ, Ratain MJ.

Pharmacogenomics. 2013 Sep;14(12):1383-7. doi: 10.2217/pgs.13.134.

33.

Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.

Bhatta SS, Wroblewski KE, Agarwal KL, Sit L, Cohen EE, Seiwert TY, Karrison T, Bakris GL, Ratain MJ, Vokes EE, Maitland ML.

Oncologist. 2013;18(8):965-70. doi: 10.1634/theoncologist.2013-0006. Epub 2013 Jul 30.

34.

Time to tumor growth: a model end point and new metric system for oncology clinical trials.

Maitland ML, Schwartz LH, Ratain MJ.

J Clin Oncol. 2013 Jun 10;31(17):2070-2. doi: 10.1200/JCO.2013.49.3635. Epub 2013 May 6. No abstract available.

PMID:
23650409
35.

Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients.

Sharma MR, Karrison TG, Kell B, Wu K, Turcich M, Geary D, Kang SP, Takebe N, Graham RA, Maitland ML, Schilsky RL, Ratain MJ, Cohen EE.

Clin Cancer Res. 2013 Jun 1;19(11):3059-67. doi: 10.1158/1078-0432.CCR-12-3829. Epub 2013 Apr 3.

36.

High titers of autoantibodies to glutamate decarboxylase in type 1 diabetes patients: epitope analysis and inhibition of enzyme activity.

Hampe CS, Maitland ME, Gilliam LK, Phan TH, Sweet IR, Radtke JR, Bota V, Ransom BR, Hirsch IB.

Endocr Pract. 2013 Jul-Aug;19(4):663-8. doi: 10.4158/EP12318.OR.

37.

More sound cancer therapy biomarker development with active noise control.

Maitland ML.

Oncologist. 2013;18(3):239-41. doi: 10.1634/theoncologist.2013-0030. Epub 2013 Mar 13. No abstract available.

38.

Estimation of renal cell carcinoma treatment effects from disease progression modeling.

Maitland ML, Wu K, Sharma MR, Jin Y, Kang SP, Stadler WM, Karrison TG, Ratain MJ, Bies RR.

Clin Pharmacol Ther. 2013 Apr;93(4):345-51. doi: 10.1038/clpt.2012.263. Epub 2012 Dec 27.

39.

Cancer pharmacogenomics: strategies and challenges.

Wheeler HE, Maitland ML, Dolan ME, Cox NJ, Ratain MJ.

Nat Rev Genet. 2013 Jan;14(1):23-34. doi: 10.1038/nrg3352. Epub 2012 Nov 27. Review.

40.

Of mast and mean: differential-temperature cue makes mast seeding insensitive to climate change.

Kelly D, Geldenhuis A, James A, Penelope Holland E, Plank MJ, Brockie RE, Cowan PE, Harper GA, Lee WG, Maitland MJ, Mark AF, Mills JA, Wilson PR, Byrom AE.

Ecol Lett. 2013 Jan;16(1):90-8. doi: 10.1111/ele.12020. Epub 2012 Nov 1.

PMID:
23113938
41.

Models of excellence: improving oncology drug development.

Sharma MR, Maitland ML, Ratain MJ.

Clin Pharmacol Ther. 2012 Nov;92(5):548-50. doi: 10.1038/clpt.2012.99.

42.

Why RECIST works and why it should stay--reply to counterpoint.

Sharma MR, Maitland ML, Ratain MJ.

Cancer Res. 2012 Oct 15;72(20):5158. doi: 10.1158/0008-5472.CAN-12-1988. Epub 2012 Sep 4. No abstract available.

43.

RECIST: no longer the sharpest tool in the oncology clinical trials toolbox---point.

Sharma MR, Maitland ML, Ratain MJ.

Cancer Res. 2012 Oct 15;72(20):5145-9; discussion 5150. doi: 10.1158/0008-5472.CAN-12-0058. Epub 2012 Sep 4.

44.

Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.

Cohen EE, Wu K, Hartford C, Kocherginsky M, Eaton KN, Zha Y, Nallari A, Maitland ML, Fox-Kay K, Moshier K, House L, Ramirez J, Undevia SD, Fleming GF, Gajewski TF, Ratain MJ.

Clin Cancer Res. 2012 Sep 1;18(17):4785-93. doi: 10.1158/1078-0432.CCR-12-0110. Epub 2012 Aug 7.

45.

Purposeful exercise, including bicycle transportation, improves health.

Maitland ME.

Clin J Sport Med. 2012 May;22(3):292-3. doi: 10.1097/JSM.0b013e318256e797. No abstract available.

PMID:
22544063
46.

Advances in biomarkers for targeted agents.

Maitland ML.

Clin Adv Hematol Oncol. 2011 Sep;9(9):688-90. No abstract available.

PMID:
22402514
47.

On "Disability reconsidered: the paradox..." Roush SE, Sharby N. Phys Ther. 2011;91:1715-1727.

Maitland ME.

Phys Ther. 2012 Mar;92(3):469; author reply 469-71. doi: 10.2522/ptj.2012.92.3.469.1. No abstract available.

PMID:
22383687
48.

Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors.

Steingart RM, Bakris GL, Chen HX, Chen MH, Force T, Ivy SP, Leier CV, Liu G, Lenihan D, Lindenfeld J, Maitland ML, Remick SC, Tang WH.

Am Heart J. 2012 Feb;163(2):156-63. doi: 10.1016/j.ahj.2011.10.018. Review.

PMID:
22305831
49.

Resampling phase III data to assess phase II trial designs and endpoints.

Sharma MR, Karrison TG, Jin Y, Bies RR, Maitland ML, Stadler WM, Ratain MJ.

Clin Cancer Res. 2012 Apr 15;18(8):2309-15. doi: 10.1158/1078-0432.CCR-11-1815. Epub 2012 Jan 27.

50.

Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth.

Kakodkar NC, Peddinti RR, Tian Y, Guerrero LJ, Chlenski A, Yang Q, Salwen HR, Maitland ML, Cohn SL.

Pediatr Blood Cancer. 2012 Oct;59(4):642-7. doi: 10.1002/pbc.24004. Epub 2011 Dec 6.

PMID:
22147414

Supplemental Content

Loading ...
Support Center